ATE125535T1 - Tricyclische aromatische verbindungen. - Google Patents

Tricyclische aromatische verbindungen.

Info

Publication number
ATE125535T1
ATE125535T1 AT89115497T AT89115497T ATE125535T1 AT E125535 T1 ATE125535 T1 AT E125535T1 AT 89115497 T AT89115497 T AT 89115497T AT 89115497 T AT89115497 T AT 89115497T AT E125535 T1 ATE125535 T1 AT E125535T1
Authority
AT
Austria
Prior art keywords
sub
sup
aromatic compounds
tricyclic aromatic
nitrogen
Prior art date
Application number
AT89115497T
Other languages
English (en)
Inventor
O William Lever Jr
Harry Jefferson Leighton
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10583945&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE125535(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wellcome Found filed Critical Wellcome Found
Application granted granted Critical
Publication of ATE125535T1 publication Critical patent/ATE125535T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D313/00Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • C07D313/02Seven-membered rings
    • C07D313/06Seven-membered rings condensed with carbocyclic rings or ring systems
    • C07D313/10Seven-membered rings condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C07D313/12[b,e]-condensed
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/38Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to acyclic carbon atoms and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D313/00Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • C07D313/02Seven-membered rings
    • C07D313/06Seven-membered rings condensed with carbocyclic rings or ring systems
    • C07D313/10Seven-membered rings condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C07D313/14[b,f]-condensed
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00Systems containing at least three condensed rings
    • C07C2603/02Ortho- or ortho- and peri-condensed systems
    • C07C2603/04Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/30Ortho- or ortho- and peri-condensed systems containing three rings containing seven-membered rings
    • C07C2603/32Dibenzocycloheptenes; Hydrogenated dibenzocycloheptenes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrane Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT89115497T 1985-08-17 1986-08-15 Tricyclische aromatische verbindungen. ATE125535T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB858520662A GB8520662D0 (en) 1985-08-17 1985-08-17 Tricyclic aromatic compounds

Publications (1)

Publication Number Publication Date
ATE125535T1 true ATE125535T1 (de) 1995-08-15

Family

ID=10583945

Family Applications (3)

Application Number Title Priority Date Filing Date
AT86306326T ATE51867T1 (de) 1985-08-17 1986-08-15 Tricyclische verbindungen.
AT88121224T ATE97401T1 (de) 1985-08-17 1986-08-15 Tricyclische verbindungen.
AT89115497T ATE125535T1 (de) 1985-08-17 1986-08-15 Tricyclische aromatische verbindungen.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
AT86306326T ATE51867T1 (de) 1985-08-17 1986-08-15 Tricyclische verbindungen.
AT88121224T ATE97401T1 (de) 1985-08-17 1986-08-15 Tricyclische verbindungen.

Country Status (13)

Country Link
US (1) US4871865A (de)
EP (3) EP0351887B1 (de)
JP (2) JPH0739346B2 (de)
AT (3) ATE51867T1 (de)
DE (3) DE3670290D1 (de)
ES (1) ES2001519A6 (de)
GB (1) GB8520662D0 (de)
GR (1) GR862137B (de)
HK (1) HK97593A (de)
HU (1) HU201520B (de)
IL (1) IL79729A (de)
PT (1) PT83202B (de)
SG (1) SG38393G (de)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6310784A (ja) * 1986-03-03 1988-01-18 Kyowa Hakko Kogyo Co Ltd 抗アレルギー剤
JPH07116174B2 (ja) * 1987-02-27 1995-12-13 協和醗酵工業株式会社 ジベンズ〔b,e〕オキセピン誘導体
AU605501B2 (en) * 1987-08-25 1991-01-17 Kyowa Hakko Kirin Co., Ltd. Dibenz(b,e)oxepin derivative and antiallergic agent
US4882351A (en) * 1987-10-14 1989-11-21 Roussel Uclaf Tricyclic compounds
AU612437B2 (en) * 1987-12-14 1991-07-11 Kyowa Hakko Kogyo Co. Ltd. Tricyclic compounds
CA1338625C (en) * 1988-06-09 1996-10-01 Kyowa Hakko Kogyo Co., Ltd. Tricyclic compounds
US5242931A (en) * 1988-06-09 1993-09-07 Kyowa Hakko Kogyo Co., Ltd. Tricyclic compounds as TXA2 antagonists
US5208238A (en) * 1989-06-19 1993-05-04 Burroughs Wellcome Company Agents for potentiating the effects of antitumor agents and combating multiple drug resistance
GB8914040D0 (en) * 1989-06-19 1989-08-09 Wellcome Found Agents for potentiating the effects of antitumour agents and combating multiple drug resistance
GB8914061D0 (en) * 1989-06-19 1989-08-09 Wellcome Found Agents for potentiating the effects of antitumour agents and combating multiple drug resistance
CA2059127A1 (en) * 1989-06-19 1990-12-20 Oscar William Lever Medicaments useful in cancer therapy and having antihistaminic properties
GB8914060D0 (en) * 1989-06-19 1989-08-09 Wellcome Found Agents for potentiating the effects of antitumour agents and combating multiple drug resistance
CA2073078A1 (en) * 1991-07-09 1993-01-10 Tatsuya Hashinaga Semiconductor device testing apparatus
US5641805A (en) * 1995-06-06 1997-06-24 Alcon Laboratories, Inc. Topical ophthalmic formulations for treating allergic eye diseases
US5899727A (en) 1996-05-02 1999-05-04 Advanced Micro Devices, Inc. Method of making a semiconductor isolation region bounded by a trench and covered with an oxide to improve planarization
DE19848200A1 (de) * 1998-10-20 2000-04-27 Basf Ag Verfahren zur Trocknung von Phenoxymethylbenzoesäuren
US6174914B1 (en) 1999-06-15 2001-01-16 Alcon Laboratories, Inc. Method of inhibiting cytokine release from human ocular cells
CA2374002A1 (en) 1999-06-18 2000-12-28 Alcon Laboratories, Inc. Topical ophthalmic mast cell stabilizers for treating allergic eye diseases
US6174878B1 (en) 1999-08-31 2001-01-16 Alcon Laboratories, Inc. Topical use of kappa opioid agonists to treat otic pain
US20040097486A1 (en) * 1999-11-18 2004-05-20 Yanni John M. Use of an H1 antagonist and a safe steroid to treat eye conditions
DE60109742T2 (de) 2000-01-25 2005-08-18 Alcon Inc. Antiallergische ophthalmische zubereitungen, geeignet zur anwendung mit kontaktlinsen
DK1284722T3 (da) 2000-05-19 2005-09-19 Alcon Inc Sammensætninger indeholdende et benzamiddisulfidderivat til behandling af allergiske sygdomme
AU2001255675B2 (en) 2000-05-19 2005-04-14 Alcon, Inc. Disulfide derivatives useful for treating allergic diseases
DK1289945T3 (da) 2000-05-19 2004-11-01 Alcon Inc Anilindisulfidderivater til behandling af allergiske sygdomme
US7977376B2 (en) 2001-06-27 2011-07-12 Novartis Ag Olopatadine formulations for topical nasal administration
TWI231759B (en) * 2001-06-27 2005-05-01 Alcon Inc Olopatadine formulations for topical administration
AU2002366567B2 (en) * 2001-12-05 2006-11-16 Alcon, Inc. Use of an H1 antagonist and a safe steroid to treat rhinitis
US20050209312A1 (en) * 2004-03-19 2005-09-22 Bausch & Lomb Incorporated Carboxylic acid derivatives of doxepin formulations preserved with low-irritation preservative
ZA200610350B (en) * 2004-06-28 2008-12-31 Alcon Inc Topical formulations for treating allergic diseases
ES2253996B1 (es) * 2004-07-28 2007-08-16 Urquima, S.A. Procedimiento para la preparacion del acido 11-((z)-3-(dimetilamino)propiliden)-6,11-dihidrodibenz(b,e)oxepinacetico.
AU2005309951B2 (en) * 2004-11-24 2011-07-07 Alcon, Inc. Method of delivering nasal spray
EP1971590A2 (de) 2005-12-22 2008-09-24 Medichem, S.A. Kristalline polymorphe formen von olopatadinhydrochlorid und verfahren zu ihrer herstellung
US7950020B2 (en) * 2006-03-16 2011-05-24 Ntt Docomo, Inc. Secure operating system switching
US7687646B2 (en) * 2006-03-28 2010-03-30 Azad Pharmaceutical Ingredients, Ag Polymorphic forms of olopatadine hydrochloride and methods for producing olopatadine and salts thereof
US8445437B2 (en) * 2006-07-27 2013-05-21 The Brigham And Women's Hospital, Inc. Treatment and prevention of cardiovascular disease using mast cell stabilizers
US20080139531A1 (en) * 2006-12-04 2008-06-12 Alcon Manufacturing Ltd. Use of connective tissue mast cell stabilizers to facilitate ocular surface re-epithelization and wound repair
KR20100014858A (ko) 2007-02-07 2010-02-11 알콘, 인코퍼레이티드 국소 비강 투여용 올로파타딘 제제
CH698773B1 (de) * 2007-02-16 2011-06-30 Sumitomo Chemical Co Verfahren zur Herstellung einer Dibenzoxepin-Verbindung.
US20090182035A1 (en) * 2007-04-11 2009-07-16 Alcon Research, Ltd. Use of a combination of olopatadine and cilomilast to treat non-infectious rhinitis and allergic conjunctivitis
TW200902025A (en) * 2007-04-11 2009-01-16 Alcon Res Ltd Use of an inhibitor of TNF α plus an antihistamine to treat allergic rhinitis and allergic conjunctivitis
US8445435B2 (en) * 2007-09-28 2013-05-21 The Brigham And Women's Hospital, Inc. Mast cell stabilizers in the treatment of obesity
US8410285B2 (en) * 2008-03-20 2013-04-02 Lek Pharmaceuticals D.D. 2′-halobiphenyl-4-yl intermediates in the synthesis of angiotensin II antagonists
US10517839B2 (en) * 2008-06-09 2019-12-31 Cornell University Mast cell inhibition in diseases of the retina and vitreous
ES2433715T3 (es) * 2008-07-16 2013-12-12 Crystal Pharma, S.A.U. Procedimiento de obtención de olopatadina e intermedios
JP5564060B2 (ja) * 2009-02-05 2014-07-30 ザック システム エス.ピー.エー. オロパタジン及び/又はその薬学的に許容され得る塩の製造方法
IT1397503B1 (it) 2009-04-21 2013-01-16 F S I Fabbrica Italiana Sint Processo per la preparazione di olopatadina
EP2453872B1 (de) 2009-07-17 2013-08-21 Alcon Research, Ltd. Olopatadin-nasenspraybehandlung für kinder
WO2011027322A1 (en) 2009-09-03 2011-03-10 Ranbaxy Laboratories Limited Extended release dosage form containing olopatadine for oral administration
US20110082145A1 (en) 2009-10-01 2011-04-07 Alcon Research, Ltd. Olopatadine compositions and uses thereof
TWI544922B (zh) 2011-05-19 2016-08-11 愛爾康研究有限公司 高濃度歐羅派特錠(olopatadine)眼用組成物
US9145383B2 (en) 2012-08-10 2015-09-29 Hallstar Innovations Corp. Compositions, apparatus, systems, and methods for resolving electronic excited states
WO2014025370A1 (en) 2012-08-10 2014-02-13 Hallstar Innovations Corp. Tricyclic energy quencher compounds for reducing singlet oxygen generation
US9370483B2 (en) 2013-09-13 2016-06-21 Glenmark Specialty S.A. Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
US9937189B2 (en) 2013-09-13 2018-04-10 Glenmark Specialty S.A. Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
HRP20211515T1 (hr) 2013-09-13 2021-12-24 Glenmark Specialty S.A. Stabilni farmaceutski pripravak u fiksnoj dozi koji sadrži mometazon i olopatadin, namijenjen nazalnoj primjeni
US10758550B2 (en) 2013-10-04 2020-09-01 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
CN112773808A (zh) 2013-10-04 2021-05-11 格兰马克专业公司 使用莫米松和奥洛他定的组合治疗过敏性鼻炎
US10548907B2 (en) 2013-10-04 2020-02-04 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US10016443B2 (en) 2013-10-04 2018-07-10 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US10653661B2 (en) 2013-10-04 2020-05-19 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
PL3104854T3 (pl) 2014-02-10 2020-11-30 Respivant Sciences Gmbh Stabilizatory komórek tucznych do leczenia choroby płuc
WO2015120389A1 (en) 2014-02-10 2015-08-13 Patara Pharma, LLC Mast cell stabilizers treatment for systemic disorders
US11679210B2 (en) 2014-10-03 2023-06-20 Glenmark Specialty S.A. Dispensing device and pharmaceutical composition for the treatment of rhinitis
US10265296B2 (en) 2015-08-07 2019-04-23 Respivant Sciences Gmbh Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
WO2017027387A1 (en) 2015-08-07 2017-02-16 Patara Pharma, LLC Methods for the treatment of mast cell related disorders with mast cell stabilizers
EP3506893A4 (de) 2016-08-31 2020-01-22 Respivant Sciences GmbH Cromolynzusammensetzungen zur behandlung von chronischem husten aufgrund von idiopathischer pulmonaler fibrose
JP2019531308A (ja) 2016-10-07 2019-10-31 レシュピファント サイエンシス ゲゼルシャフト ミット ベシュレンクター ハフトゥングRespivant Sciences Gmbh 肺線維症の治療のためのクロモリン組成物
SG11202112592YA (en) 2018-02-23 2021-12-30 Glenmark Specialty Sa Treatment of allergic rhinitis in pediatric subjects using a combination of mometasone and olopatadine
US12303635B2 (en) 2018-04-16 2025-05-20 Glenmark Specialty S.A. Dispensing device and pharmaceutical composition for the treatment of rhinitis
EP4058010A1 (de) 2019-11-12 2022-09-21 Institut National de la Santé et de la Recherche Médicale (INSERM) Verwendung von mastzellenstabilisator zur behandlung von herzversagen mit konservierter ausstossfraktion
US20240374555A1 (en) * 2023-04-10 2024-11-14 Magi's Lab Srl Mast Cell Stabilizer with Sodium Cromoglycate-based Inhibitor for Preventing Lipedema Progression

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL58901C (de) * 1957-02-07 1947-02-15
DE1232161B (de) * 1961-10-07 1967-01-12 Boehringer & Soehne Gmbh Verfahren zur Herstellung von basisch substituierten Dibenzo-oxepinen und deren Salzen
BE641498A (de) * 1962-03-13
US3401192A (en) * 1962-07-17 1968-09-10 Merck & Co Inc Esters of 5h-dibenzo [a, d] cycloheptene
US3420851A (en) * 1962-12-19 1969-01-07 Pfizer & Co C Novel dibenzoxepines
US3509175A (en) * 1963-10-14 1970-04-28 Pfizer & Co C Recovery of pure cis 11-(3-dimethylaminopropylidene) - 6,11 - dihydrodibenz(b,e)oxepine from admixture with its trans isomer
GB1076612A (en) * 1964-07-24 1967-07-19 Merck & Co Inc Dibenzocycloheptene derivatives
FR2138257B1 (de) * 1971-05-21 1974-08-23 Roussel Uclaf
OA04603A (fr) * 1973-03-02 1980-06-30 Rhone Poulenc Sa Nouveaux dérivés du dibenzo [a,d] cycloheptene, leurs sels et leur préparation.
US3966820A (en) * 1974-07-05 1976-06-29 Syntex (U.S.A.) Inc. 2-Substituted-5-oxo-5H-dibenzo-[A,D]cycloheptenes, the esters and ethers thereof, having pharmaceutical activity, and methods and compositions for the use thereof
JPS5139683A (ja) * 1974-10-02 1976-04-02 Dai Ichi Kogyo Seiyaku Co Ltd Jibenzookisebinjudotaino seizoho
JPS5516590A (en) * 1978-07-21 1980-02-05 Nec Corp Television relay broadcasting equipment
US4282365A (en) * 1978-11-24 1981-08-04 Merck & Co., Inc. Dibenz[b,e]oxepin compounds
US4307245A (en) * 1978-12-29 1981-12-22 Syva Company Amitriptyline conjugates to antigenic proteins and enzymes
US4223013A (en) * 1978-12-29 1980-09-16 Syva Company Amitriptyline conjugates to antigenic proteins and enzymes
JPS56156273A (en) * 1980-03-31 1981-12-02 Dainippon Pharmaceut Co Ltd Acetic derivative
US4412999A (en) * 1982-04-14 1983-11-01 Merck & Co., Inc. Anti-emetic esters of cyproheptadine-3-carboxylic acid and structurally related compounds
JPS6028972A (ja) * 1983-06-29 1985-02-14 Kyowa Hakko Kogyo Co Ltd ジベンゾ[b,e]オキセピン誘導体

Also Published As

Publication number Publication date
ATE97401T1 (de) 1993-12-15
GR862137B (en) 1986-12-30
JP2556821B2 (ja) 1996-11-27
DE3689311D1 (de) 1993-12-23
DE3689311T2 (de) 1994-03-10
HUT41761A (en) 1987-05-28
EP0316022A2 (de) 1989-05-17
EP0214779B1 (de) 1990-04-11
PT83202A (en) 1986-09-01
EP0316022A3 (en) 1989-10-11
EP0214779A1 (de) 1987-03-18
ES2001519A6 (es) 1988-06-01
DE3650357T2 (de) 1996-01-04
JPS6245557A (ja) 1987-02-27
JPH0739346B2 (ja) 1995-05-01
EP0316022B1 (de) 1993-11-18
JPH07165749A (ja) 1995-06-27
DE3650357D1 (de) 1995-08-31
GB8520662D0 (en) 1985-09-25
IL79729A (en) 1990-11-05
EP0351887B1 (de) 1995-07-26
HK97593A (en) 1993-09-24
PT83202B (pt) 1989-03-30
IL79729A0 (en) 1986-11-30
HU201520B (en) 1990-11-28
US4871865A (en) 1989-10-03
SG38393G (en) 1993-06-11
EP0351887A1 (de) 1990-01-24
DE3670290D1 (de) 1990-05-17
ATE51867T1 (de) 1990-04-15

Similar Documents

Publication Publication Date Title
ATE125535T1 (de) Tricyclische aromatische verbindungen.
DK126389D0 (da) Peptidforbindelser
ES8500231A1 (es) Un metodo para preparar compuestos de piridilo
GB1425606A (en) Cyclohexenone derivatives
ES8506676A1 (es) Un metodo para preparar derivados de fenotiazina
GB1465769A (en) Carbamates of ergolines
GB1449078A (en) Phenoxyethylamine derivatives
ES556048A0 (es) Un procedimiento para la preparacion de un derivado de tiazolidina.
AU586089B2 (en) Phosphodiesterace type 111 inhibitors having a thiadiazinone ring as part of a tricyclic structure
ES8600762A1 (es) Un procedimiento para la preparacion de nuevos compuestos de beta-lactama.
ATE44741T1 (de) 2-(n-substituierte guanidino)-4heteroarylthiazole als mittel gegen geschwuere.
GB1127170A (en) New tricyclic amines, the preparation and compositions containing same
NZ222973A (en) Substituted piperidine and azepine derivatives and pharmaceutical compositions
TH17758A (th) สารเคมี

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties